Akebia Therapeutics, Inc. (AKBA)Healthcare | Drug Manufacturers - Specialty & Generic | Cambridge, United States | NasdaqCM
1.38 USD
-0.02
(-1.429%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:58 a.m. EDT
The long-term investment case is severely compromised by deteriorating fundamentals. Despite a recent price rally, the company is burning cash with negative operating margins and a massive debt load relative to equity. Revenue growth has turned negative, and the return on equity is deeply negative, indicating capital destruction. The market has correctly priced this as a value trap; the low share price does not reflect a bargain but rather a business struggling to generate sustainable profits. While the recent price action shows some recovery, the underlying operational metrics remain broken. In the short term, the outlook is murky. The stock is trading below its 200-day average, suggesting lingering weakness, though it has recently bounced off lower levels. However, the statistical forecasting model offers no directional guidance, showing a flat prediction with low confidence, which aligns with the chaotic nature of a distressed biotech stock. The heavy put activity confirms that retail and institutional traders are wary of further declines. There is no dividend income to offset these risks. The company is not generating enough free cash flow to support shareholder returns, and the balance sheet is fragile. Investors should view this as a speculative gamble on a turnaround rather than an investment in a healthy business. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.269749 |
| AutoARIMA | 0.275827 |
| AutoETS | 0.275837 |
| AutoTheta | 0.312055 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 2.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.142 |
| Excess Kurtosis | -0.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 721.549 |
| Revenue per Share | 0.877 |
| Market Cap | 370,196,384 |
| Forward P/E | -7.26 |
| Beta | 0.24 |
| Profit Margins | -8.83% |
| Website | https://www.akebia.com |
As of July 11, 2026, 5:58 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts at strikes below the current price ($1.00 and $1.50) across multiple expirations. Call activity is concentrated at the money and slightly out-of-the-money, but the volume of put buying suggests a dominant bearish sentiment or a hedge against further volatility, rather than a bullish breakout expectation.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6473552 |
| Address1 | 245 First Street |
| Address2 | Suite 1400 |
| All Time High | 31.0 |
| All Time Low | 0.241 |
| Ask | 1.72 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 5,983,270 |
| Average Daily Volume3 Month | 5,089,063 |
| Average Volume | 5,089,063 |
| Average Volume10Days | 5,983,270 |
| Beta | 0.235 |
| Bid | 0.9864 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.102 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.38 |
| Current Ratio | 1.4 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.39 |
| Day Low | 1.34 |
| Debt To Equity | 721.549 |
| Display Name | Akebia Therapeutics |
| Earnings Call Timestamp End | 1,778,155,200 |
| Earnings Call Timestamp Start | 1,778,155,200 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | 12,130,000 |
| Ebitda Margins | 0.05219 |
| Enterprise To Ebitda | 33.395 |
| Enterprise To Revenue | 1.743 |
| Enterprise Value | 405,076,384 |
| Eps Current Year | -0.105 |
| Eps Forward | -0.19 |
| Eps Trailing Twelve Months | -0.08 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 871 2099 |
| Fifty Day Average | 1.12284 |
| Fifty Day Average Change | 0.25715995 |
| Fifty Day Average Change Percent | 0.22902635 |
| Fifty Two Week Change Percent | -64.73552 |
| Fifty Two Week High | 4.04 |
| Fifty Two Week High Change | -2.6599998 |
| Fifty Two Week High Change Percent | -0.6584158 |
| Fifty Two Week Low | 0.823 |
| Fifty Two Week Low Change | 0.557 |
| Fifty Two Week Low Change Percent | 0.6767922 |
| Fifty Two Week Range | 0.823 - 4.04 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,395,322,200,000 |
| Float Shares | 262,013,191 |
| Forward Eps | -0.19 |
| Forward P E | -7.263158 |
| Free Cashflow | 65,809,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 194 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.81941 |
| Gross Profits | 190,432,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04059 |
| Held Percent Institutions | 0.42116 |
| Implied Shares Outstanding | 268,258,243 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Akebia Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 370,196,384 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_36644983 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -20,511,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 375,561,540 |
| Number Of Analyst Opinions | 5 |
| Open | 1.37 |
| Operating Cashflow | 60,372,000 |
| Operating Margins | -0.02764 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 871 2098 |
| Previous Close | 1.4 |
| Price Eps Current Year | -13.142858 |
| Price Hint | 4 |
| Price To Book | 13.529412 |
| Price To Sales Trailing12 Months | 1.5929003 |
| Profit Margins | -0.08826 |
| Quick Ratio | 1.295 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -1.42857 |
| Regular Market Day High | 1.39 |
| Regular Market Day Low | 1.34 |
| Regular Market Day Range | 1.34 - 1.39 |
| Regular Market Open | 1.37 |
| Regular Market Previous Close | 1.4 |
| Regular Market Price | 1.38 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 3,378,150 |
| Return On Assets | 0.02016 |
| Return On Equity | -0.78955 |
| Revenue Growth | -0.066 |
| Revenue Per Share | 0.877 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 268,258,243 |
| Shares Percent Shares Out | 0.0715 |
| Shares Short | 19,177,371 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 27,420,606 |
| Short Name | Akebia Therapeutics, Inc. |
| Short Percent Of Float | 0.0726 |
| Short Ratio | 3.1 |
| Source Interval | 15 |
| State | MA |
| Symbol | AKBA |
| Target High Price | 6.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 4.2 |
| Target Median Price | 4.0 |
| Total Cash | 162,644,000 |
| Total Cash Per Share | 0.606 |
| Total Debt | 197,524,000 |
| Total Revenue | 232,404,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.08 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.587435 |
| Two Hundred Day Average Change | -0.20743501 |
| Two Hundred Day Average Change Percent | -0.13067308 |
| Type Disp | Equity |
| Volume | 3,378,150 |
| Website | https://www.akebia.com |
| Zip | 2,142 |